The role of epidermal proteolysis in overdesquamation was revealed in Netherton syndrome, a rare ichthyosis due to genetic deficiency of the LEKTI inhibitor of serine proteases. Recently, we developed activography, a new histochemical method, to spatially localize and semiquantitatively assess proteolytic activities using activitybased probes. Activography provides specificity and versatility compared to in situ zymography, the only available method to determine enzymatic activities in tissue biopsies. Here, activography was validated in skin biopsies obtained from an array of distinct disorders and compared with in situ zymography. Activography provides a methodological advancement due to its simplicity and specificity and can be readily adapted as a routine diagnostic assay. Interestingly, the levels of epidermal proteolysis correlated with the degree of desquamation independent of skin pathology. Thus, deregulated epidermal proteolysis likely represents a universal mechanism underlying aberrant desquamation.
| BACKG ROU N D
Epidermal desquamation is a physiological process regulated by proteolytic pathways involving serine proteases, especially kallikrein-related peptidases (KLKs), and other enzymes, for example, cathepsins. Various skin disorders display altered epidermal desquamation. [1] [2] [3] [4] Recently, we developed a new histochemical method termed activography that allows the fine mapping of enzymatic activities on tissue sections. It is based on the reaction of an activity-based probe (ABP) with the active form of the corresponding enzyme in clinical/biological samples and detection of the ABP adduct with typical histochemical reagents. [5] Here, activography was validated side-by-side with in situ zymography to investigate the levels and spatial localization of proteolytic activities in skin biopsies obtained from patients with distinct diseases manifested by abnormal epidermal desquamation. Aberrant proteolysis due to KLK5 hyperactivity has been causally implicated in epidermal inflammation and overdesquamation in Netherton syndrome (NS). [6, 7] Recently, we reported that in acral peeling skin syndrome (APSS), epidermal proteolytic activities are aberrantly elevated likely due to the lack or diminished expression of endogenous protease inhibitors. [8] Interestingly, KLK5 has been implicated in the development of atopic dermatitis (AD) skin architecture [9] and altered expression of KLKs has been observed in AD patients. [10] In X-linked ichthyosis (XLI), there is accumulation of cholesterol sulphate, a putative inhibitor of serine proteases, [11] but whether proteolytic activities in the epidermis are altered has not been investigated as also in seborrheic dermatitis (SD), ichthyosis vulgaris (ΙV) and autosomal recessive congenital ichthyosis due to TGM1 mutations (ARCI-TGM1). Overall, the findings presented here suggest that abnormal epidermal proteolytic activities underlie the aberrant desquamating phenotype in many more inflammatory, desquamating skin disorders.
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| QUE S TIONS ADDRE SS ED
We validated activography as a new assay to map the epidermal proteolytic activities in skin biopsies obtained from patients suffering from various skin diseases that affect epidermal desquamation. [7] d 60% or 50% body surface coverage. e Activity was found in the dermis.
| E XPERIMENTAL DE S I G N
f Absence of shedding was assessed based on the clinical image of the patient.
in Table 1 . Activography was conducted with the B24P ABP that reacts with active serine proteases and esterases. [2] In situ zymography [2, 8] and immunohistochemistry (IHC) were conducted as described. [6] Detailed experimental conditions are found in Supporting Information.
| RE SULTS AND D ISCUSS I ON
All healthy controls (n = 5) exhibited "low" staining that was localized at the stratum granulosum (SG) and stratum corneum (SC), compatible with the known protein expression pattern of KLKs. In accordance, they displayed low caseinolytic activities using in situ zymography at the SG and SC. Representative images of activography and in situ zymography are shown in Figure 1 , and findings are summarized in Table 1 . Table 1 ). In two other APSS patients, activography staining correlated with the severity of desquamation, ( Figure S1A , Table 1 ).
Using activography, proteolytic activities were spatially mapped and quantified in AD, XLI, ARCI (TGM1) and IV skin ( Figure 1 , Table 1 ).
Elevated activities were also observed in SD, a severe form of dandruff characterized by altered corneocyte cohesion and abnormal corneodesmosome degradation. The enhanced proteolytic activities could be related to both mechanisms. The previously reported increased expression of the serine protease inhibitors LEKTI (lymphoepithelial Kazal-type-related inhibitor) and SCCA1 (squamous cell carcinoma antigen) in dandruff could reflect compensatory mechanisms. [12] Biopsies from three AD patients exhibiting different degrees of skin inflammation and serum IgE levels were analysed, and the levels of proteolysis correlated with phenotype severity ( Figure   S1A , Table 1 ). In XLI and IV, almost no proteolysis is observed, consistent with hyperkeratosis and diminished desquamation. A slight staining in SC/SG junction in XLI may be attributed to low serine protease activities reminiscent of healthy specimens. Both ARCI-TGM1 samples showed loss of epidermal proteolytic activities consistent with diminished desquamation. However, similarly to XLI, slight staining was found at the SC/SG junction of ARCI1 specimen. Increased dermal staining with activography in ARCI2 could suggest the presence of active serine proteases with low caseinolytic activities in the dermis.
Immunohistochemical staining for KLK5 in healthy, NS, AD, APSS and SD samples resembled activography staining ( Figure S1B ), consistent with the fact that KLK5 plays important roles in NS, [6] AD [9, 10] and APSS [8] pathology. KLK6 colocalizes with KLK5, and its staining is like activography ( Figure S1C ).
Using activography, we associated abnormalities in the levels of epidermal proteolysis with corresponding alterations (up or down)
in the extent of desquamation in a variety of skin disorders. Except for NS, where the causative gene encodes a protease inhibitor, in the other skin diseases studied here, abnormal proteolysis was not known to be a pathological feature. We propose the concept that deregulated proteolysis could be a unifying feature in diseases characterized by abnormal desquamation. A subset of clinical specimens was also analysed with gelatin in situ zymography to determine the specificity of activography. Since matrix metalloproteinases are the main gelatinolytic enzymes, the B24P should not provide identical results to gelatin in situ zymography. Indeed, the pattern of gelatinolytic activities was completely different from that of caseinolytic activities and activography ( Figure 1B) . Specifically, no gelatinolytic activities were detected in most samples, except for APSS that showed high activity only in SC. To provide evidence for the specificity of B24P, skin biopsies were pretreated with aprotinin and AEBSF that effectively inhibit activity of serine proteases ( Figure S2 ). It should be mentioned that these controls should always run in parallel with the experiments as also suggested and performed previously, [13, 14] especially in this case that the B24P does not have a proteolytic enzyme-selective "bait"
and its specificity merits further characterization.
| CON CLUS IONS
Activity-based probes have a well-recognized ability to visualize proteases in vivo. [13, 14] Here, we showed that activography provides similar spatial and semiquantitative information as the in situ zymography method but is advantageous in that activography allows the mapping of enzyme specificities thus opening possibilities for new applications in clinical diagnostic laboratories. In the present study, the B24P-ABP used does not have proteolytic enzyme-selective "bait,"
and therefore, it is expected to react with both proteases and esterases. However in skin, using the appropriate control inhibitors, it was demonstrated that B24P mainly reacts with proteases. The development of highly specific ABPs that could react with only one enzyme will enable spatial localization of the active forms of unique enzymes.
Finally, we highlight for the first time that deregulated skin proteolysis is a common feature in a wide range of distinct skin diseases, all characterized though, by aberrant desquamation and barrier defect.
This could open a new window targeting proteolytic pathways.
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